NEW YORK (GenomeWeb) – MolecularMD today announced it has received approval from the New York State Department of Health for its Notch 1 gene mutation test.

The next-generation sequencing-based test is intended to support clinical trial enrollment, the firm said in a statement, and uses FFPE tissue and whole blood samples. The test has a five-day turnaround time.

Notch 1 mutations have been linked to cancers such as chronic lymphocytic leukemia and mantle cell lymphoma and put patients at greater risk for poor outcomes and reduced overall survival.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.